PPAR-alpha: Therapeutic role in diabetes-related cardiovascular disease

Diabetes, Obesity and Metabolism

Volumn 10, Issue 9, 2008, Pages 691-698

  Cheng, Alice Y Y ^a,b,c   Leiter, Lawrence A ^a,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CREDIT VALLEY HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e NONE   (Canada)

Author keywords

Cardiovascular disease; Diabetes mellitus; Fibrate; FIELD; PPAR alpha

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; LUNG EMBOLISM; MEDLINE; MONOTHERAPY; NONHUMAN; OUTCOMES RESEARCH; PANCREATITIS; PRIMARY PREVENTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT;

EID: 50249168289     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00747.x     Document Type: Review

References (44)

1. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology - molecular mechanisms and clinical implications. Vasc Pharmacol 2006; 45: 19-28.
2. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580.
3. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-5348.
4. Staels B, Vu-Dac N, Kosykh VA et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95: 705-712.
5. Fruchart JC. Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am J Cardiol 2001; 88 (Suppl.): 24N-29N.
6. Vu-Dac N, Schoonjans K, Kosykh V et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferators-activated receptor. J Clin Invest 1995; 96: 741-750.
7. Chou CJ, Haluzik M, Gregory C et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002; 277: 24484-24489.
8. Kim H, Haluzik M, Asghar Z et al. Peroxisome proliferators-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003; 52: 1770-1778.
9. Ye JM, Doyle PJ, Iglesias MA et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 2001; 50: 411-417.
10. Ravnskjaer K, Boergesen M, Rubi B et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrinology 2005; 146: 3266-3276.
11. Marx N, Sukhova GK, Collins T et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
12. Lee H, Shi W, Tontonoz P et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000; 87: 516-521.
13. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-598.
14. Chinetti G, Griglio S, Antonucci M et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-25580.
15. Goya K, Sumitani S, Xu X et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 659-663.
16. Irukayama-Tomobe Y, Miyauchi T, Kasuya Y et al. Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes. J Cardiovasc Pharmacol 2004; 44: S358-S361.
17. Durrington PN, Mackness MI, Bhatnagar K et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type Iib hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217-225.
18. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006; 5: 145-156.
19. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-276.
20. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004; 3: 101-111.
21. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferators-activated receptors (PPAR)-coagonism: The bezafibrate lessons. Cardiovasc Diabetes 2005; 4: 14-19.
22. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dylipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
23. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease: Risk in the Helsinki Heart Study. Circulation 1992; 85: 37-45.
24. Koskinen P, Manttari M, Manninen V et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
25. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
26. Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-1563.
27. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med 2002; 162: 2597-2604.
28. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-27.
29. Tenenbaum A, Motro M, Fisman EZ et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.
30. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905-910.
31. Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.
32. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 2005; 366: 1849-1861.
33. Verges B. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Curr Opin Lipidol 2006; 17: 653-658.
34. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 16115-16122.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
36. Coulhoun HM, Betteridge DJ, Durrington PN et al.; for the Collaborative Atorvastatin Diabetes Study (CARDS) investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
37. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006; 22: 913-927.
38. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3121-3143.
39. Grundy SM, Cleeman JI, Bariey Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 720-732.
40. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015-2222.
41. Syvanne M, Whittall RA, Trupeinen U et al. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 2004; 172: 267-272.
42. Leiter LA. The prevention of diabetic microvascular complications of diabetes: Is there a role of lipid lowering? Diab Res Clin Prac 2005; 68 (Suppl. 2): S3-S14.
43. Park CW, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-1517.
44. ACCORD trial. Available from URL: http://www.accordtrial.org (accessed 22 January, 2007)